Zobrazeno 1 - 10
of 29
pro vyhledávání: ''
Autor:
Ali Al-Zahrani, Taher Al-Tweigeri, Osama Al Malik, Asma Tulbah, Adher Al-Sayed, Said Dermime, Mohamed Alshabanah, Adnan Ezzat, Naser Elkum, Dahish Ajarim
Publikováno v:
BASE-Bielefeld Academic Search Engine
BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 222 (2007)
BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 222 (2007)
Background Breast cancer in young Saudi women is a crucial problem. According to the 2002 annual report of Saudi National Cancer Registry, breast cancers that developed before the age of 40 comprise 26.4% of all female breast cancers comparing to 6.5
Publikováno v:
BMC cancer, 16:712. BioMed Central Ltd.
BMC Cancer
BMC Cancer
Background: Response-guided neoadjuvant chemotherapy (RG-NACT) with magnetic resonance imaging (MRI) is effective in treating oestrogen receptor positive/human epidermal growth factor receptor-2 negative (ER-positive/HER2-negative) breast cancer. We
Autor:
Jin Seok Ahn, Yoon-La Choi, Hyun Jung Jun, Yeon Hee Park, Myung Hee Chang, Eun Yoon Cho, Min Jae Park, Young-Hyuck Im, Ji Eun Uhm, Do Hyoung Lim, Sang Hoon Ji, Kyoung Ha Kim, Seong Yoon Yi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
Background We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype. Methods A retrospective analysis
Autor:
Jan G. Hengstler, Marco Johannes Battista, D. Boehm, Susanne Gebhard, Antje Lebrecht, Marcus Schmidt, Christine Solbach, W. Siggelkow, Heinz Koelbl, Cristina Cadenas, Rosemarie Marchan, Birte Hellwig, Jörg Rahnenführer, Isabel Sicking, M. Gehrmann
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 562 (2012)
BMC Cancer
BMC Cancer
Background Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed. Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant systemic therapy (n = 766). Metho
Autor:
Christian F. Singer, Dietmar Pils, Dan Tong, Andrea Wolf, Margaretha Rudas, Gerda Hofstetter, Ingrid Schiebel, Nicole Concin, Georg Heinze, Robert Zeillinger
Publikováno v:
BMC Cancer, Vol 10, Iss 1, p 682 (2010)
BMC Cancer
BMC Cancer
Background Gene expression of peripheral myelin protein 22 (PMP22) and the epithelial membrane proteins (EMPs) was found to be differentially expressed in invasive and non-invasive breast cell lines in a previous study. We want to evaluate the progno
Publikováno v:
BMC Cancer, Vol 10, Iss 1, p 228 (2010)
BMC Cancer
BMC Cancer
Background The 2007 St Gallen international expert consensus statement describes three risk categories and provides recommendations for treatment of early breast cancer. The set of recommendations on how to best treat primary breast cancer is recogni
Autor:
Karin Jirström, Donal J. Brennan, William M. Gallagher, Elton Rexhepaj, Michael J. Duffy, Darran P. O'Connor, Sallyann L. O'Brien, Göran Landberg
Publikováno v:
BMC Cancer
BMC Cancer; 10 (2010)
BMC Cancer, Vol 10, Iss 1, p 639 (2010)
BMC Cancer; 10 (2010)
BMC Cancer, Vol 10, Iss 1, p 639 (2010)
Background Conflicting data exist regarding the prognostic and predictive impact of survivin (BIRC5) in breast cancer. We previously reported survivin cytoplasmic-to-nuclear ratio (CNR) as an independent prognostic indicator in breast cancer. Here, w
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 320 (2010)
BMC Cancer, Vol 10, Iss 1, p 320 (2010)
Background Tumor hypoxia is marked by enhanced expression of hypoxia-inducible factor-α (HIF-1α) and glucose transporter-1 (Glut-1). Hypoxic conditions have also been associated with overexpression of angiogenic factors, such as leptin. The aim of
The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer
Autor:
Tibor Krenács, Zsuzsanna Varga, Cosima Riemenschnitter, Janina Kulka, Cornelia Leo, Barna Wichmann, Ivett Teleki, Holger Moch, Marcell A Szász, Bärbel Papassotiropoulos
Publikováno v:
BMC Cancer, Vol 13, Iss 1, p 50 (2013)
BMC Cancer
BMC Cancer
Background Several classification systems are available to assess pathological response to neoadjuvant chemotherapy in breast cancer, but reliable biomarkers to predict the efficiency of primary systemic therapy (PST) are still missing. Deregulation
Autor:
Anita Bane, Amy Gillgrass, Kay Dias, John A. Hassell, Mark Levine, Robin M. Hallett, Jessica G. Cockburn, Timothy J. Whelan
Publikováno v:
BMC Cancer
Background Lymph node (LN) status is the most important prognostic variable used to guide ER positive (+) breast cancer treatment. While a positive nodal status is traditionally associated with a poor prognosis, a subset of these patients respond wel